FDA warned 30 telehealth companies over GLP-1 claims. Here's what they got wrong.

The FDA issued 30 warning letters to telehealth companies on March 3, 2026 for false or misleading claims about compounded GLP-1 products. What the violations were and how to evaluate what you're being sold.

If you've seen ads for GLP-1 medications through a telehealth company, you've probably noticed the messaging is often vague about whether the medication is FDA-approved or what you're actually getting. That vagueness is the point — and it's exactly what the FDA's latest enforcement action targeted.

On March 3, 2026, the FDA announced 30 warning letters to telehealth companies for making false or misleading claims about compounded GLP-1 products. It was the second enforcement wave since the agency launched a crackdown in September 2025, and the violations share a pattern worth knowing.

The FDA's press release identified two primary patterns across the 30 warning letters:

1. Implying sameness with FDA-approved products. Companies made claims suggesting their compounded GLP-1 products were equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound. They're not. Compounded drugs are not FDA-approved, which means the FDA has not reviewed them for safety, effectiveness, or quality before marketing.

2. Branding compounded products without disclosure. Some telehealth companies advertised GLP-1 medications under the company's own name or trademark, without making clear that a different entity actually compounded the drug or disclosing who that entity was. This obscures the supply chain from patients.

"It's a new era. We are paying close attention to misleading claims being made by telehealth and pharma companies across all media platforms — and taking swift action," said FDA Commissioner Marty Makary, M.D., M.P.H. "Compounded drugs can be important for overcoming shortages or meeting unique patient needs — but compounders should not try to compound drugs in a way that circumvents FDA's approval process."

FDA-approved drugs go through a review process that examines safety, effectiveness, and manufacturing quality before the product reaches patients. Compounded drugs do not. They're made by a pharmacy or outsourcing facility under different legal rules, and the FDA has not reviewed their safety, effectiveness, or quality before they're sold.

A generic drug is not the same as a compounded drug. Generics are FDA-approved — they've gone through rigorous review and must demonstrate bioequivalence to the brand. There is currently no FDA-approved generic semaglutide or generic tirzepatide.

The FDA has been explicit about this distinction. When a telehealth company implies that a compounded product is equivalent to an FDA-approved drug, the FDA considers that misleading.

When you receive a compounded GLP-1 medication:

• The FDA has not reviewed it for safety, effectiveness, or quality
• The active ingredient, dosing, and manufacturing standards may differ from pharmacy to pharmacy
• There are no labeling requirements equivalent to those for FDA-approved drugs
• Storage, stability, and sterility were not reviewed by the FDA

This doesn't automatically mean a compounded product is unsafe or ineffective. It means the quality information is held at the pharmacy level — not verified through any federal review process.

Some patients have legitimate reasons to use compounded medications: the FDA-approved version is unavailable, there's a documented medical need for a different formulation, or cost and access are real barriers. These are valid clinical conversations. The problem the FDA is targeting is marketing that obscures these distinctions from patients.

Based on the violation patterns in the warning letters, here are specific signals to watch for:

• Phrases like "same as Ozempic," "identical formula," or "the same medication" without qualification
• A GLP-1 product branded under the telehealth company's name, with no mention of what pharmacy actually compounded it
• No clear statement that the medication is compounded and not FDA-approved
• Effectiveness claims that cite no specific trials or FDA approval decisions
• Prices dramatically lower than FDA-approved versions with no explanation of what makes them different

None of these signals automatically proves a company is acting in bad faith. But they are the specific patterns the FDA identified as misleading.

If you're using a telehealth company for a GLP-1 prescription:

• Ask the company to confirm the name and address of the pharmacy that actually compounds your medication
• Look up that pharmacy's name against your state's pharmacy licensing board (most states have online lookup tools)
• Ask your prescriber whether the pharmacy is a licensed 503A pharmacy or a 503B outsourcing facility, and what that distinction means for your situation
• Look for a clear written statement on any paperwork that the drug is compounded and not FDA-approved

Warning letters are notices, not final enforcement actions. Companies that receive them have the opportunity to respond and come into compliance. Whether any named companies will face stronger action depends on their responses.

The broader question of compounded GLP-1 access is also evolving. The FDA's April 30, 2026 proposal to exclude semaglutide and tirzepatide from the 503B bulks list adds another layer of uncertainty for patients who depend on compounded versions.

• Is the GLP-1 you're prescribing me compounded? If so, which pharmacy compounds it?
• Is this drug FDA-approved, or is it a compounded version?
• Can you provide a written statement that this medication is compounded and not FDA-approved?
• Can I see the pharmacy's state license information?

---

Medical disclaimer: This content is for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

Sources

• FDA press release, March 3, 2026: fda.gov
• FDA compounding Q&A: fda.gov
• FDA BeSafeRx: fda.gov